Search company, investor...
Omniscient Neurotechnology company logo

Omniscient Neurotechnology

o8t.com

Founded Year

2019

Stage

Series B | Alive

Total Raised

$29.42M

Valuation

$0000 

Last Raised

$29.42M | 3 yrs ago

About Omniscient Neurotechnology

Omniscient Neurotechnology is a data company that operates in the healthcare and technology sectors, with a focus on brain-related disorders. The company offers solutions that process and analyze complex brain network data, known as connectomics, to provide actionable insights for neurosurgeons and researchers. These insights are used to enhance patient care and facilitate research in the field of neurology. It was founded in 2019 and is based in Sydney, New South Wales.

Headquarters Location

580 George St, Level 10

Sydney, New South Wales, 2000,

Australia

Loading...

Omniscient Neurotechnology's Product Videos

Omniscient Neurotechnology's Products & Differentiators

    Quicktome

    AI software for the brain

Loading...

Expert Collections containing Omniscient Neurotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Omniscient Neurotechnology is included in 3 Expert Collections, including Digital Health.

D

Digital Health

10,804 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

M

Mental Health Tech

742 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

O

Oncology Tech

457 items

This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.

Omniscient Neurotechnology Patents

Omniscient Neurotechnology has filed 50 patents.

The 3 most popular patent topics include:

  • neuroimaging
  • magnetic resonance imaging
  • medical imaging
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/12/2021

12/19/2023

Neuroimaging, Magnetic resonance imaging, Rotating disc computer storage media, Neuroscience, Computer memory

Grant

Application Date

7/12/2021

Grant Date

12/19/2023

Title

Related Topics

Neuroimaging, Magnetic resonance imaging, Rotating disc computer storage media, Neuroscience, Computer memory

Status

Grant

Latest Omniscient Neurotechnology News

Omniscient secures FDA approval for MRI-based brain mapping software

Jun 5, 2023

The brain-mapping software, dubbed Quicktome Functional Connectome (FC), is designed to map the functional connectivity patterns of a patient’s brain, responsible for key functions such as movement, language, and vision, in a single MRI scan Quicktome FC by Omniscient Neurotechnology. (Credit: Omniscient Neurotechnology) Omniscient has secured the US Food and Drug Administration (FDA) approval for its new functional brain mapping software, Quicktome Functional Connectome (FC). Quicktome FC, a major upgrade to the company’s existing Quicktome platform, can map the functional connectivity patterns of a patient’s brain in a single MRI scan. The Quicktome platform, which is used in neurosurgical applications, has been extended to provide connectomic insights for a wide range of neurological disciplines. The upgrade also includes Connectomics Discovery Mode, which offers access to powerful experimental connectomic analysis tools in a research setting. Quicktome FC facilitates the use of functional MRI data for connectomic outlier detection, to enable the creation of neurological biomarkers for various disorders, said the company. Omniscient chief medical officer Michael Sughrue said: “Today’s clearance is a landmark moment, not only for Omniscient but for the entire field of clinical neuroscience. “As a clinician, I’ve faced the frustration of not being able to comprehensively care for patients due to a lack of patient-specific, precision brain data. This clearance will help transform how brains are assessed in routine patient care.” Omniscient has integrated resting-state functional MRI (rs-fMRI) technology into its Quicktome platform to provide a safe, non-invasive imaging option for neurological disorders. The rs-fMRI scans are safe, painless, and non-invasive, and are used to measure the brain network connections while the patient is at rest. Quicktome FC is the first neurological planning and visualisation tool to leverage rs-fMRI. The FDA approval allows clinicians to analyse the brain network activity crucial for functions like movement, speech, and vision, without needing specialised technicians or patient tests. Omniscient intends to commercialise the functional brain-mapping technology in a significant software release this year. Omniscient CEO Stephen Scheeler said: “Omniscient’s mission is to improve the lives of billions through using AI to decode the human brain – a field known as connectomics. “We are entering an exciting new era where we can provide clinicians with the precise, personalised data to understand an individual’s brain function beyond merely generalised symptoms and chemistry. “This technology offers medicine a new horizon of neurological understanding and precision treatment.” Do you have interesting content to share with us? Enter your email address so we can get in touch. Related Article

Omniscient Neurotechnology Frequently Asked Questions (FAQ)

  • When was Omniscient Neurotechnology founded?

    Omniscient Neurotechnology was founded in 2019.

  • Where is Omniscient Neurotechnology's headquarters?

    Omniscient Neurotechnology's headquarters is located at 580 George St, Level 10, Sydney.

  • What is Omniscient Neurotechnology's latest funding round?

    Omniscient Neurotechnology's latest funding round is Series B.

  • How much did Omniscient Neurotechnology raise?

    Omniscient Neurotechnology raised a total of $29.42M.

  • Who are the investors of Omniscient Neurotechnology?

    Investors of Omniscient Neurotechnology include Gina Rinehart, Will Vicars, Kerr Neilson and Gretel Packer.

  • Who are Omniscient Neurotechnology's competitors?

    Competitors of Omniscient Neurotechnology include Synaptive Medical and 2 more.

  • What products does Omniscient Neurotechnology offer?

    Omniscient Neurotechnology's products include Quicktome.

  • Who are Omniscient Neurotechnology's customers?

    Customers of Omniscient Neurotechnology include Baptist South Florida, Advent health, University of West Virginia and Westchester Medical Center.

Loading...

Compare Omniscient Neurotechnology to Competitors

QMENTA Logo
QMENTA

QMENTA is a medical imaging platform. The cloud-based platform uses information from magnetic resonance imaging (MRI) and computerized tomography (CT) brain images to improve drug development and clinical care for brain diseases. It was founded in 2013 and is based in Boston, Massachusetts.

Translational Imaging Innovations Logo
Translational Imaging Innovations

Translational Imaging Innovations is a company focused on integrating imaging science workflows and advanced analytics for research and clinical trials in the ophthalmology and vision science sector. The company offers a unified suite of applications that address the workflow and data management needs of ophthalmology and vision science investigators in a secure environment. These applications help manage study workflows, organize complex data and images, and simplify compliance processes. It was founded in 2019 and is based in Hickory, North Carolina.

G
Gesund.ai

Gesund.ai provides a platform focusing on the clinical validation of medical artificial intelligence (AI) solutions and provides machine-learning algorithmic solutions. It offers hospitals, pharmaceutical firms, or researchers the medical learning infrastructure needed to develop an AI-based ecosystem that fully abides by data standards while allowing users to work together on problems without centralizing or sharing data. The company was founded in 2021 and is based in Cambridge, Massachusetts.

BenchSci Logo
BenchSci

Benchsci develops a research intelligence platform. It uses artificial intelligence and machine learning to translate closed and open-access data into recommendations for specific experiments regarding antibody extraction. Benchsci was formerly known as Scinapsis. It was founded in 2015 and is based in Toronto, Canada.

Stryker Logo
Stryker

Stryker (NYSE: SYK) develops, manufactures, and markets specialty surgical and medical products worldwide. It offers orthopedic implants, trauma systems, powered surgical instruments, endoscopic systems, and, patient care and handling equipment. It was founded in 1941 and is based in Kalamazoo, Michigan.

Brainlab Logo
Brainlab

Brainlab is a pioneer in digital medical technology, operating in the healthcare sector. The company's main offerings include software-driven medical solutions that digitize, automate, and optimize clinical workflows for various surgical procedures and radiotherapy. These solutions primarily cater to physicians, medical professionals, and their patients. It was founded in 1989 and is based in Munich, Germany.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.